To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
Summary
What This Bill Does
This bill disapproves most of HHS's February 2, 2024 final rule on Medications for the Treatment of Opioid Use Disorder. The rule, published at 89 Fed. Reg. 7549, would have no force or effect except for the portion that modifies subpart B of 42 C.F.R. part 8, which relates to accreditation of opioid treatment programs. The practical effect is to block the rule's non-accreditation changes while preserving the accreditation-related updates for opioid treatment programs.
Who Benefits and How
Opioid treatment programs benefit from preservation of the rule's accreditation-related modifications. Clinicians opposed to the 2024 non-accreditation rule changes benefit because those provisions would have no force or effect. Members of Congress opposing SAMHSA rule changes benefit from a statutory rollback of most of the final rule. Accreditation organizations benefit because the bill preserves the subpart B accreditation portion.
Who Bears the Burden and How
SAMHSA opioid treatment regulators must stop implementing the non-accreditation portions of the final rule. Patients relying on non-accreditation flexibilities in the 2024 rule may lose those regulatory changes. Opioid treatment program compliance staff must distinguish preserved accreditation changes from nullified rule provisions. HHS legal staff must update guidance and enforcement posture after the rule is partly nullified.
Key Provisions
- Provides that the HHS Medications for the Treatment of Opioid Use Disorder final rule has no force or effect.
- Preserves the portion of the final rule modifying accreditation of opioid treatment programs.
- Requires HHS and SAMHSA to distinguish nullified non-accreditation provisions from preserved accreditation rules.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Nullifies the HHS final rule titled Medications for the Treatment of Opioid Use Disorder, published February 2, 2024 at 89 Fed. Reg. 7549, except the portion modifying accreditation of opioid treatment programs in 42 C.F.R. part 8 subpart B.
Key Policy Areas
Opioid Treatment, HHS Regulation, Substance Use Disorder
Primary Purpose
Nullifies the HHS final rule titled Medications for the Treatment of Opioid Use Disorder, published February 2, 2024 at 89 Fed. Reg. 7549, except the portion modifying accreditation of opioid treatment programs in 42 C.F.R. part 8 subpart B.
Policy Domains
Resolution provisions
Identified Gains
- Opioid treatment programs
- Clinicians opposed to 2024 rule changes
- Members of Congress opposing SAMHSA changes
- Accreditation organizations
Identified Costs
- SAMHSA opioid treatment regulators
- Patients relying on rule flexibilities
- Opioid treatment compliance staff
- HHS legal staff
Sponsors
Legislative Progress
In CommitteeMrs. Houchin introduced the following bill; which was referred to …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Opioid treatment compliance staff, Opioid treatment programs
Positive-direction: Opioid treatment programs
Negative-direction: Opioid treatment compliance staff
HHS legal staff, SAMHSA opioid treatment regulators
Patients relying on rule flexibilities
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology